MS
SNDX icon

Maven Securities’s Syndax Pharmaceuticals SNDX Stock Holding History

Maven Securities’s Portfolio SNDX Stock Details SNDX Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2022
Q1 		– Sell
-23,529
Closed -$515K – 1093
2021
Q4 		$515K Buy
+23,529
New +$435K 0.01% 551
2021
Q1 		– Sell
-150,000
Closed -$3.43M – 1278
2020
Q4 		$3.43M Buy
+150,000
New +$3.11M 0.34% 71

Other funds holding SNDX

APM
Avidity Partners Management Dallas, Texas $624M AUM 250.2% 1-Year Est. Return
BlackRock
BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return
FLSM
Frazier Life Sciences Management Palo Alto, California $4.59B AUM 237.58% 1-Year Est. Return
NCM
Nantahala Capital Management New Canaan, Connecticut $3.01B AUM 119.46% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
BI
BVF Inc San Francisco, California $3.91B AUM 304.52% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $3.38T AUM 44.17% 1-Year Est. Return
ACA
Avoro Capital Advisors New York $11.1B AUM 207.82% 1-Year Est. Return
O
OrbiMed New York $5.4B AUM 163.13% 1-Year Est. Return
PHS
PFM Health Sciences San Francisco, California $1.17B AUM 92.19% 1-Year Est. Return

Maven Securities's SNDX Position: Q1 2022 in Review

Maven Securities sold out of Syndax Pharmaceuticals (SNDX) in Q1 2022, closing a stake of 23,529 shares — an estimated $515K sold.

Maven Securities first reported a position in SNDX in Q4 2020 and held it in 2 quarters. The position peaked at $3.43M in Q4 2020. 136 funds tracked by Wall St. Rank hold SNDX as of Q1 2022.

  • Maven Securities reported no remaining Syndax Pharmaceuticals position as of Q1 2022 after selling out during the quarter.
  • Maven Securities sold 23,529 Syndax Pharmaceuticals shares in Q1 2022, an estimated $515K.
  • Maven Securities first reported a position in Syndax Pharmaceuticals in Q4 2020 and held it in 2 quarters.
  • Maven Securities's Syndax Pharmaceuticals position peaked at $3.43M in Q4 2020.
  • 136 funds tracked by Wall St. Rank held Syndax Pharmaceuticals as of Q1 2022.

Based on Maven Securities's 13F filing for Q1 2022, filed 16 May 2022.